These study results are published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Mammographic density refers to the proportion of the breast that appears dense on a mammogram; it is one of the strongest risk factors for primary invasive breast cancer. On a mammogram, dense tissue looks white while non-dense tissue looks dark grey. The dense area consists primarily of breast ducts and connective tissue, while the non-dense tissue is mostly fat.
Results of a previous study showed that patients with DCIS who had higher mammographic density had about two to three times increased risk for a second breast cancer.
To confirm her earlier findings, Laurel A. Habel, Ph.D., research scientist at Kaiser Permanente’s Division of Research, and colleagues conducted a larger cohort study that consisted of 935 women diagnosed with DCIS who were treated with breast-conserving surgery (i.e., not a mastectomy) between 1990 and 1997 at Kaiser Permanente of Northern California.
After reviewing medical records, evaluating mammograms at diagnosis and then calculating the risk of subsequent breast cancer events during follow-up, the researchers found that risk of second breast cancer appeared to be elevated among the women with higher density.
“While risk was elevated for both breasts, the increase was greatest and most consistent for the breast opposite to the one with the initial cancer,” Habel said.
Of the patients, 164 had a subsequent ipsilateral breast cancer (breast cancer on the original cancer-affected breast) and 59 had a new primary cancer in the other breast during follow-up. The researchers anticipated finding an increased risk of a subsequent cancer in the breast with the initial cancer, as well as in the opposite breast.
Habel stressed that additional studies will be needed to confirm these risk estimates and determine whether information on density can aid in risk assessment and treatment options.
“Information on mammographic density may help with treatment decisions for ductal carcinoma in situ patients,” she said. “While it’s not a strong enough risk factor on its own, it may be possible to combine it with other factors to improve risk assessment and inform treatment decisions.”
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.